All In Biotech

Drug Trial Radar · NCT07285239

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Nov 2031

Study completion Jun 2034

Sponsor

Lead sponsor
PrECOG, LLC.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GlaxoSmithKline
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Eligible participants with newly diagnosed myeloma who are not considered eligible or refuse bone marrow transplant will be enrolled. Participants will be randomized to either belantamab mafodotin or daratumumab given in combination with bortezomib, lenalidomide and dexamethasone. Treatment will continue until disease progression, unacceptable side effects or withdrawal of consent. Belantamab mafodotin is a targeted cancer treatment that works against multiple myeloma cells. It combines a homing device (an antibody) with a powerful cell-killing drug (a toxin), delivering the toxin directly to cancer cells while largely sparing healthy cells. Minimal residual disease (MRD) testing will be done on bone marrow samples obtained standardly during your treatment. MRD shows whether a very small number of cancer cells can still be detected after treatment, even if standard lab tests shows no signs of cancer. The purpose of this study is to evaluate if belantamab mafodotin, bortezomib, lenalidomide and dexamethasone (BVRd) improves minimal residual disease (MRD) negative status and/or prolongs progression-free survival (PFS) compared with daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) in participants with newly diagnosed multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • Arm A: Belantamab MafodotinDrug

    1.9 milligram/kilogram (mg/kg) intravenous (IV) will be administered every 8 weeks for first 24 weeks (Cycles 1-3), then 1.9 mg/kg every 12 weeks (Cycles 4+) until progression, unacceptable toxicity or participant withdrawal

  • Arm B: Daratumumab HyaluronidaseDrug

    1800 mg subcutaneous (SC) will be administered weekly from Week 1-8 (Cycles 1 and 2), every 2 weeks from Week 9-24 (Cycles 3-6), and every 4 weeks from Week 25 (Cycles 7+) onwards until progression, unacceptable toxicity or participant withdrawal

  • BortezomibDrug

    1.3 milligrams per square meter (mg /m²) SC on days 1, 8 and 15 of every 28 day bortezomib treatment cycle for 8 cycles

  • LenalidomideDrug

    25 mg orally (PO) Days 1-21 of every 28 day lenalidomide treatment cycle.

  • DexamethasoneDrug

    40 mg PO on Days 1, 8, 15, and 22 of each 28-day cycle (may decrease to 20 mg if \>75 years old)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MRD Negative StatusTime frame: Up to 86 months
  2. Progression-Free Survival (PFS)Time frame: Up to 86 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Iowa Oncology Research Associates

    Des Moines, Iowa · Recruiting

  • Northern Lights / Eastern Maine Medical Center

    Brewer, Maine · Recruiting

  • Gundersen Lutheran

    La Crosse, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.